Innealta Capital’s Vir Biotechnology VIR Stock Holding History

Innealta Capital’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-3,541	Closed	-$31.5K	–	1635
2024 Q2	$31.5K	Buy	+3,541	New	+$34K	0.01%	492

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Innealta Capital's VIR Position: Q3 2024 in Review

Innealta Capital sold out of Vir Biotechnology (VIR) in Q3 2024, closing a stake of 3,541 shares — an estimated $31.5K sold.

Innealta Capital first reported a position in VIR in Q2 2024 and held it in 1 quarter. The position peaked at $31.5K in Q2 2024. 197 funds tracked by Wall St. Rank hold VIR as of Q3 2024.

Innealta Capital reported no remaining Vir Biotechnology position as of Q3 2024 after selling out during the quarter.
Innealta Capital sold 3,541 Vir Biotechnology shares in Q3 2024, an estimated $31.5K.
Innealta Capital first reported a position in Vir Biotechnology in Q2 2024 and held it in 1 quarter.
Innealta Capital's Vir Biotechnology position peaked at $31.5K in Q2 2024.
197 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.